跳转至内容
Merck
CN

M-072

二甲双胍标准液 CRM 盐酸盐 溶液

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C4H12ClN5
化学文摘社编号:
分子量:
165.62
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-659-6
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

二甲双胍标准液 CRM 盐酸盐 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

InChI key

OETHQSJEHLVLGH-UHFFFAOYSA-N

InChI

1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H

SMILES string

Cl.CN(C)C(=N)NC(N)=N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

Quality Level

Gene Information

General description

Snap-N-Spike® 参考溶液适用于临床毒理学中LC-MS/MS或GC/MS研究。二甲双胍是一种抗糖尿病药,其可通过抑制肝脏产生葡萄糖发生作用。该双胍类似物专门用于治疗2型糖尿病。

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

F O Magalhães et al.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 38(8), 513-517 (2006-08-31)
The present study was designed to determine the effects of metformin on the forearm glucose uptake and blood flow after an oral glucose challenge. Eleven normal subjects, and ten non-obese type 2 diabetes patients without medication of anti-hyperglycemic drug and
D Carter et al.
Diabetes, obesity & metabolism, 4(6), 424-427 (2002-10-31)
The antidiabetic biguanide metformin has been shown to increase faecal excretion of bile salts in type 2 diabetes. Cultured human intestinal Caco-2 cell monolayers provide a model of human enterocytes. These monolayers are used here to determine the effect of
F Robert et al.
Diabetes & metabolism, 29(3), 279-283 (2003-08-12)
Although the existence of a deep compartment for metformin has long been hypothesized, there is still little direct information concerning metformin distribution in individual tissues in man. The only available study involves chronic metformin therapy. In that study, the measurement
Gerald G Briggs et al.
Obstetrics and gynecology, 105(6), 1437-1441 (2005-06-04)
To determine whether metformin is excreted into breast milk and whether this exposure adversely affects the blood glucose of nursing infants. Seven women were started on metformin 500 mg twice daily on the first day after cesarean delivery. Breastfeeding was
Dennis C Gore et al.
The Journal of trauma, 59(2), 316-322 (2005-11-19)
Both insulin and metformin have been shown to attenuate hyperglycemia and reduce net muscle protein catabolism following burn injury. The purpose of this study was to compare the peripheral metabolic effects of insulin and metformin in severe burn patients. Six

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持